Metabolic & Cardiometabolic
tirzepatide causes greater weight loss than semaglutide
In plain terms: Does tirzepatide (Zepbound/Mounjaro) take off more weight than semaglutide (Wegovy/Ozempic)?
Leans support Metabolic & Cardiometabolic 💰 Industry COI noted🔬 Includes disconfirming
Part of: 💊 GLP-1 Drugs
RefutedContestedStrong support
consensus score 0.54
Yes — the head-to-head SURMOUNT-5 trial and network meta-analyses show tirzepatide produces several percentage points more weight loss than semaglutide.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
14 support 1 contradict 1 tested null 5 mixed · 21 sources, 15 independent groups · 1 superseded — pooled inside a review, counted once
The evidence (24)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Cetiner S. 2026 · study_type: observational | observational | supports | low | Real-world, non-diabetic obesity, n small single-center (Istanbul): tirzepatide produced greater 36-week weight loss than semaglutide and liraglutide (exact % not given, p<0.01 for all-arm weight reduction). |
| Brown A et al 2026 · study_type: observational | observational | supports | moderate | Real-world two-center cohort: per-protocol 1y TWL semaglutide 7.2% vs tirzepatide 11.7% (and consistent at 2-3y); ITT showed similar direction. |
| Johansson E et al] # corrected 2026-08-17 from PubMed; was [Wang 2026 · J Med Econ | observational | supports | low | Cost-effectiveness analysis built on SURMOUNT-5 confirms greater weight loss with tirzepatide as its efficacy premise. |
| McGowan 2025 · Nat Med | meta-analysis | supports | high | SR/MA of obesity pharmacotherapy: tirzepatide ranks above semaglutide for weight loss magnitude. |
| Damen 2026 · Ann Intern Med | meta-analysis | mixed | moderate | The prior extract ('tirzepatide among most efficacious for weight loss, ahead of semaglutide') overstates the paper: it does not rank tirzepatide above semaglutide, it pairs them. Results: 'Semaglutide probably reduced mortality and major adverse cardiovascular events (MACE), and both semaglutide and tirzepatide led to the greatest weight loss compared with placebo and/or LI in pairwise and network meta-analyses.' Conclusion: 'Semaglutide and tirzepatide showed the most favorable results across outcomes.' Limitation stated by the authors: 'Direct head-to-head comparisons of different treatments were limited.' So a 69-study / 112 511-participant network that contains both drugs declines to separate them - equivocal for a claim asserting one is greater than the other, hence MIXED rather than supports. Quality moderate rather than high FOR THIS CLAIM: the review is well conducted, but the specific contrast rests on sparse direct evidence by the authors' own account. Whether the full-text NMA league table reports a tirzepatide-vs-semaglutide estimate cannot be told from the abstract; flagged for full-text follow-up. Read from abstract only (2026-08-19). |
| Lin RT et al] # corrected 2026-08-17 from PubMed; was [Zhou 2024 · Metabolism | meta-analysis | supports | moderate | MASLD NMA ranks GLP-1/GIP polyagonists above GLP-1RA on weight, consistent with tirzepatide>semaglutide. |
| Murugadoss K et al 2026 · Preprints.org | observational | supports | low | Sustained low-dose (0.25mg semaglutide vs 2.5mg tirzepatide) real-world comparison: tirzepatide associated with greater weight loss at low/starter doses (exact % not given). |
| de Mesquita 2023 · Int J Obes | meta-analysis | supports | moderate | Off-scope for a head-to-head claim: this meta-analysis compares tirzepatide only with PLACEBO — 'Table S2 GRADE assessment and summary of findings: Tirzepatide compared to placebo for weight reduction.' The six pooled trials (Table S1) are Frias 2018, Frias 2020, 'Heise et al., 2022', 'Jastreboff et al., 2022 (SURMOUNT-1)', 'Rosenstock et al., 2021 (SURPASS-1)' and 'Dahl et al., 2022 (SURPASS-5)'; SURPASS-2, the only tirzepatide-versus-semaglutide trial, is absent. Its own top-dose placebo-adjusted result is 'MD 12.38 lower (17.23 lower to 7.53 lower)' percent weight, not the ~21% previously recorded, and five of six trials enrolled type 2 diabetes — a population the paper's own meta-regression shows loses less weight ('HbA1c 4.8738 <0.0001'). The prior stance rested on an eyeballed cross-trial comparison the paper did not make. |
| La Vignera S et al 2026 · study_type: RCT | RCT | mixed | low | Small pilot RCT (n=90), 'optimal responder' subgroups: mean weight loss 18.2%±2.1% tirzepatide vs 16.8%±1.9% semaglutide; not an overall arm comparison. |
| Venkatakrishnan AJ et al 2026 · study_type: observational | observational | supports | moderate | Large propensity-matched real-world cohort (n=10,339 each): tirzepatide -14.7% vs semaglutide -10.8% over 2y, P<0.001; high-response rate nearly doubled with tirzepatide. |
| Nong K et al 2026 · study_type: meta-analysis | meta-analysis | mixed | high | NMA of 262 RCTs: at 1y vs lifestyle mod, tirzepatide MD -14.9% (-16.0,-13.9) vs subcutaneous semaglutide -9.8% (-10.6,-9.1) -- indirect comparison, not tirzepatide-vs-semaglutide arm. |
| Builes-Montaño CE et al 2026 · study_type: RCT | RCT | contradicts | moderate | Model-based analysis of RCT dose-response data: high probability of equivalence for semaglutide 2.4mg vs tirzepatide 10mg (99.4%) and 7.2mg vs 15mg (94.8%); equivalence driven by dose not drug identity. |
| Leslie DB et al 2026 · study_type: observational | observational | supports | moderate | Real-world Epic Cosmos cohort: adjusted probability of ≥20% weight loss + HbA1c<5.7% at 1y was 3.0% semaglutide vs 13.2% tirzepatide vs 24.0% sleeve gastrectomy. |
| Aronne 2024 · JAMA | RCT | supports | moderate | SURMOUNT-4: tirzepatide lead-in achieved 20.9% loss over 36wk, exceeding semaglutide STEP magnitudes (indirect). |
| Ghosal S et al] # corrected 2026-08-17 from PubMed; was [Verma 2026 · Eur Heart J Open | observational | tested-null | low | SURMOUNT-5 post-hoc: predicted greater CV risk reduction with tirzepatide tracks its larger weight-loss effect. |
| Matson R et al 2026 · Preprints.org | observational | mixed | low | T1D real-world: 12mo weight change -4.0% semaglutide vs -6.8% tirzepatide (both vs +... controls); not the primary study endpoint (insulin dose reduction was primary). |
| Wilding JPH, Batterham RL, Calanna S, Davies M, Kushner RF 2021 · N Engl J Med | RCT | supports | moderate | OFF-SCOPE for the head-to-head claim. This trial has no tirzepatide arm: participants were 'randomly assigned them, in a 2:1 ratio, to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention', and the contrast it reports is against placebo ('-14.9% in the semaglutide group as compared with -2.4% with placebo'). It therefore cannot vote on whether tirzepatide beats semaglutide; the prior extract supplied the -20.2% comparator from a different trial (SURMOUNT-5), which is vault reasoning across two study populations, not this paper's analysis. The head-to-head claim must be carried by the head-to-head trial itself. Read abstract-only 2026-08-19. ↩ SUPERSEDED — pooled in the review above, counted once |
| Al Ozairi E et al 2026 · study_type: observational | observational | supports | low | T1D real-world cohort: tirzepatide -10.9% vs semaglutide -9.9% vs liraglutide -7.1% at 12mo (all p<0.001); dose-dependent reductions noted. |
| Frias 2021 · N Engl J Med | RCT | mixed | high | SURPASS-2 (T2D): tirzepatide beat semaglutide on HbA1c and weight, BUT comparator semaglutide was 1mg, not the 2.4mg obesity dose. |
| Kitamoto T et al 2026 · study_type: RCT | RCT | supports | moderate | SURMOUNT-5 subpopulation (JASO obesity-disease criteria), Wk72: tirzepatide -20.1% vs semaglutide -12.9%, LSM diff -7.2 (95% CI -9.3 to -5.1), p<.001. |
| Ghusn W et al 2026 · study_type: observational | observational | supports | moderate | Real-world multicenter, 12mo TBWL%: tirzepatide 16.6%±8.6% vs semaglutide 13.4%±8.0%, P<.01; more tirzepatide users reached ≥15%/≥20% thresholds. |
| Xie 2025 · Diabetes Metab Syndr Obes | meta-analysis | tested-null | moderate | Safety-only systematic review and network meta-analysis: 'The primary outcomes were any adverse events and serious adverse events. The secondary outcomes included adverse events withdraw, hypoglycemia events (under 54 mg/dL) and other adverse events of special interest.' Weight change is absent from the extracted data ('basic characteristics ..., therapeutic interventions ..., and safety (eg, the number of relevant adverse events)') and from every result: the head-to-head findings are 'Liraglutide 3.0 mg significantly increased the incidence of any adverse events compared to semaglutide 2.4 mg (OR = 1.53, 95% CI [1.00, 2.34]), tirzepatide 10 mg (OR = 1.64, 95% CI [1.05, 2.56]) and tirzepatide 15mg (OR = 2.00, 95% CI [1.28, 3.12])'. No efficacy comparison exists to be null. |
| Hamarsheh S, Jaber AR, Abu-Khazneh O, Andonie CR, Majadleh S, Zahran A, Ayesh H 2026 · Endocrinol Diabetes Metab | meta-analysis | supports | low | Network meta-analysis, 25 RCTs / 34,259 participants, adults with overweight or obesity without diabetes. Percent body weight vs placebo: tirzepatide 15 mg MD -17.97% (95% CI -19.72 to -16.21) vs semaglutide 2.4 mg MD -11.41% (95% CI -12.74 to -10.08). League table S7.1 gives the contrast itself - tirzepatide 15 mg vs semaglutide 2.4 mg 6.55 [4.48; 8.62] percentage points (network estimate) with the DIRECT head-to-head cell 6.20 [1.82; 10.58], that direct evidence being the single open-label Lilly trial Aronne 2025 (SURMOUNT-5); at the >=20% responder threshold the contrast is RR 0.58 [0.48; 0.69] favouring tirzepatide, CINeMA Moderate. DOSE-CONDITIONAL, and this is the part the abstract does not say: against high-dose semaglutide 7.2 mg the advantage is 3.31 [-0.86; 7.48] - NULL - and CINeMA rates it 'Semaglutide 7.2 mg: Tirzepatide 15 mg | ... | Very low | Imprecision, Heterogeneity'. The paper's own certainty for the tirzepatide-15-vs-semaglutide-2.4 percent-weight comparison is 'Low | Within-study bias, Imprecision, Heterogeneity' (I2 = 89.4%; most included trials industry-sponsored). Supports the claim at licensed doses; does not establish it against semaglutide 7.2 mg. Full text + full Supporting Information read 2026-08-19; quality moderate -> low on the authors' own CINeMA rating. |
| Aronne 2025 · N Engl J Med | RCT | supports | high | SURMOUNT-5 head-to-head (obesity, no diabetes): tirzepatide -20.2% vs semaglutide -13.7% at wk72 (P<0.001); superior on all weight thresholds. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.